CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
A Phase I/IB Pilot Study of CC-486 Combined With Lenalidomide and Obinutuzumab for Relapsed/Refractory Indolent B-Cell Lymphoma
Sponsor: Celgene
This PHASE1 trial investigates Indolent B-Cell Non-Hodgkin Lymphoma and Recurrent B-Cell Non-Hodgkin Lymphoma and is currently completed. Celgene leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
May 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Oct 2024 — May 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
May 2023 — Oct 2023 [monthly]
Recruiting PHASE1
-
Jan 2022 — May 2023 [monthly]
Recruiting PHASE1
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Oct 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
- Joseph Tuscano
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .